About the Company:

Supriya Life sciences are one of the key Indian manufacturers and suppliers of active pharmaceutical ingredients (“APIs”), with a focus on research and development. As of March 31, 2021, the company has niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anesthetic, vitamin, anti-asthmatic and antiallergic. The company is the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-55% and 65-70%, respectively, of the API exports from India, between Fiscal 2017 and 2020.

In Fiscal 2021, the firm's products were exported to 78 countries to 1,060 customers including 286 distributors. The firm's API business has grown in several countries across (i) Europe, which contributed to 25.81% of revenue from operation for the nine months ended December 31, 2020; (ii) Latin America, which contributed to 12.37% of revenue from operation for the nine months ended December 31, 2020; (iii) Asia (excluding India), which contributed to 24.19% of revenue from operation for the nine months ended December 31, 2020 (iv) North America (including Canada), which contributed to 6.16% of revenue from operation for the nine months ended December 31, 2020; and (vi) India, which contributed to 23.63% of revenue from operation for the nine months ended December 31, 2020.

The firm's business operations are supported by a modern manufacturing facility located in Parshuram Lote, Maharashtra, which is approximately 250 km from Mumbai, Maharashtra. The manufacturing facility is spread across 23,806 sq. mts, having a reactor capacity of 332 KL/ day. We presently operate five cleanrooms and are setting up two new clean rooms that are expected to be commercialized in the first quarter of Fiscal 2022. The new cleanrooms will add a manufacturing capacity of 215 KL/ day.

Outstanding Litigation:

Financial Statements: